Latest:
Lurbinectedin + Atezolizumab as First-Line Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Results of the Phase 3 IMforte Trial
The Phase 3 IMforte trial demonstrated that maintenance therapy with lurbinectedin plus atezolizumab was well tolerated and explored a novel approach to extending disease control following first-line treatment in patients with extensive-stage small cell lung cancer.